Last updated on October 2017

Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study


Brief description of study

The purpose of this study is to enable continued access to RA101495 for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a RA101495 clinical study.

Clinical Study Identifier: NCT03225287

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Duarte, CA United States
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Chicago, IL United States
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Manhasset, NY United States
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Durham, NC United States
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Dallas, TX United States
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative site
Gosford, Australia
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative site
Melbourne, Australia
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Copenhagen, Denmark
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Helsinki, Finland
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Essen, Germany
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Ulm, Germany
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Budapest, Hungary
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Christchurch, New Zealand
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Hamilton, New Zealand
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Leeds, United Kingdom
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
London, United Kingdom
  Connect »